A Randomized, Double-Blind, Placebo-Controlled Study of Chemotherapy plus Cetuximab in Combination with VTX 2337 in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
ID Number 14-0343Principal Investigator(s)
Krzysztof J Misiukiewicz
Department(s) or Division(s)
Hematology and Medical Oncology
The goal of this research study is to compare the standard treatment to VTX-2337 added to the standard treatment to see if it helps your cancer tumors stop growing or shrink, and if it helps patients with SCCHN live longer. Researchers also want to determine the side effects of the experimental combination of standard treatment and VTX-2337.
In addition to the treatment part of this study, researchers plan to test samples of your tumor tissue and some of your blood to examine the impact of the study drug on tumor tissue and specific blood cells and substances. Researchers also want to know if your genes (DNA) affect how your body responds to or metabolizes (breaks down) the study drug.
Recruiting Patients: No